HomeCompareCVAC vs PM

CVAC vs PM: Dividend Comparison 2026

CVAC yields 42.92% · PM yields 3.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CVAC wins by $221.8K in total portfolio value
10 years
CVAC
CVAC
● Live price
42.92%
Share price
$4.66
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$271.5K
Annual income
$48,622.47
Full CVAC calculator →
PM
Philip Morris International
● Live price
3.49%
Share price
$164.83
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,502.61
Full PM calculator →

Portfolio growth — CVAC vs PM

📍 CVAC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCVACPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CVAC + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CVAC pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CVAC
Annual income on $10K today (after 15% tax)
$3,648.07/yr
After 10yr DRIP, annual income (after tax)
$41,329.10/yr
PM
Annual income on $10K today (after 15% tax)
$297.03/yr
After 10yr DRIP, annual income (after tax)
$2,127.22/yr
At 15% tax rate, CVAC beats the other by $39,201.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CVAC + PM for your $10,000?

CVAC: 50%PM: 50%
100% PM50/50100% CVAC
Portfolio after 10yr
$160.6K
Annual income
$25,562.54/yr
Blended yield
15.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

CVAC
Analyst Ratings
2
Buy
5
Hold
1
Sell
Consensus: Hold
Price Target
$21.00
+350.6% upside vs current
Range: $5.00 — $37.00
Altman Z
1.7
Piotroski
3/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.9% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CVAC buys
0
PM buys
0
No recent congressional trades found for CVAC or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCVACPM
Forward yield42.92%3.49%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$271.5K$49.6K
Annual income after 10y$48,622.47$2,502.61
Total dividends collected$208.4K$11.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$21.00$194.30

Year-by-year: CVAC vs PM ($10,000, DRIP)

YearCVAC PortfolioCVAC Income/yrPM PortfolioPM Income/yrGap
1← crossover$14,992$4,291.85$11,650$409.56+$3.3KCVAC
2$22,055$6,013.34$13,592$497.49+$8.5KCVAC
3$31,866$8,267.53$15,882$605.21+$16.0KCVAC
4$45,261$11,164.00$18,589$737.41+$26.7KCVAC
5$63,248$14,819.35$21,794$899.94+$41.5KCVAC
6$87,030$19,354.11$25,597$1,100.16+$61.4KCVAC
7$118,011$24,889.07$30,118$1,347.30+$87.9KCVAC
8$157,813$31,541.28$35,505$1,652.97+$122.3KCVAC
9$208,280$39,419.96$41,940$2,031.88+$166.3KCVAC
10$271,482$48,622.47$49,643$2,502.61+$221.8KCVAC

CVAC vs PM: Complete Analysis 2026

CVACStock

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Full CVAC Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this CVAC vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CVAC vs SCHDCVAC vs JEPICVAC vs OCVAC vs KOCVAC vs MAINCVAC vs MOCVAC vs BTICVAC vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.